IL33 and asthma: Recent evidence also demonstrated the potential role and effectiveness of new biological drugs directed against specific type 2 alarmin cytokines (i.e., thymic stromal lymphopoietin [TSLP], IL-25, and IL-33) in severe asthma [1,2].